Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association - PubMed (original) (raw)

. 2018 Feb 20;137(8):e30-e66.

doi: 10.1161/CIR.0000000000000556. Epub 2018 Feb 1.

Karol E Watson, Ana Barac, Theresa M Beckie, Vera Bittner, Salvador Cruz-Flores, Susan Dent, Lavanya Kondapalli, Bonnie Ky, Tochukwu Okwuosa, Ileana L Piña, Annabelle Santos Volgman; American Heart Association Cardiovascular Disease in Women and Special Populations Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research

Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association

Laxmi S Mehta et al. Circulation. 2018.

Erratum in

Abstract

Cardiovascular disease (CVD) remains the leading cause of mortality in women, yet many people perceive breast cancer to be the number one threat to women's health. CVD and breast cancer have several overlapping risk factors, such as obesity and smoking. Additionally, current breast cancer treatments can have a negative impact on cardiovascular health (eg, left ventricular dysfunction, accelerated CVD), and for women with pre-existing CVD, this might influence cancer treatment decisions by both the patient and the provider. Improvements in early detection and treatment of breast cancer have led to an increasing number of breast cancer survivors who are at risk of long-term cardiac complications from cancer treatments. For older women, CVD poses a greater mortality threat than breast cancer itself. This is the first scientific statement from the American Heart Association on CVD and breast cancer. This document will provide a comprehensive overview of the prevalence of these diseases, shared risk factors, the cardiotoxic effects of therapy, and the prevention and treatment of CVD in breast cancer patients.

Keywords: AHA Scientific Statement; breast cancer; cardiotoxicity; cardiovascular disease; oncology; prevention; risk factors.

© 2018 American Heart Association, Inc.

PubMed Disclaimer

Conflict of interest statement

The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.

Figures

Figure 1.

Figure 1.. Rates of cardiovascular disease and breast cancer in women.

Age-adjusted mortality rates of coronary heart disease (CHD) and stroke are higher than that of breast cancer. Death rates are higher in NH black women than in NH white and Hispanic women for CHD, stroke, and breast cancer. NH indicates non-Hispanic. Reprinted from Benjamin et al. Copyright © 2017, American Heart Association, Inc.

Figure 2.

Figure 2.. Risk factors for cardiovascular disease (CVD) and breast cancer.

CVD and breast cancer have shared and separate risk factors.,–

Figure 3.

Figure 3.. Factors associated with developing CVD and breast cancer.

Impact of these factors in a positive (green downward arrow, reduced risk) or negative (red upward arrow, increased risk) on developing CVD or breast cancer.,– CVD indicates cardiovascular disease.

Figure 4.

Figure 4.. Simplified depiction of detection, prevention, and treatment of left ventricular systolic dysfunction in breast cancer.

Schematic of the continuum of breast cancer treatment in relation to subsequent cardiac toxicity and heart failure. ACC indicates American College of Cardiology; ACE, angiotensin-converting enzyme; AHA, American Heart Association; CV, cardiovascular; LVEF, left ventricular ejection fraction; and MUGA, multigated acquisition. Modified from Khouri et al. Copyright © 2012, American Heart Association, Inc.

Figure 5.

Figure 5.. Echocardiographic surveillance during and after treatment with anthracycline therapy or HER2-directed therapy.

At any time during the course of surveillance imaging, if the ejection fraction is <53%, then cardiology consultation is recommended. If cardiac imaging is suboptimal, then cardiac magnetic resonance imaging should be considered. After completion of therapy, patients should undergo annual cardiovascular assessments by a provider; however, cardiac imaging should be at the discretion of the provider based on the history and physical examination. HER2 indicates human epidermal growth factor receptor 2. This Figure is based on recommendations from the consensus document for multimodality imaging in adult cancer patients prepared by the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

References

    1. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jimenez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P; on behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics: 2017 update: a report from the American Heart Association [published corrections appear in Circulation. 2017;135:e646 and Circulation. 2017;136:e196]. Circulation 2017;135:e146–e603. doi: 10.1161/CIR.0000000000000485. - DOI - PMC - PubMed
    1. Mosca L, Jones WK, King KB, Ouyang P, Redberg RF, Hill MN. Awareness, perception, and knowledge of heart disease risk and prevention among women in the United States: American Heart Association Women’s Heart Disease and Stroke Campaign Task Force. Arch Fam Med 2000;9: 506–515. - PubMed
    1. Mosca L, Hammond G, Mochari-Greenberger H, Towfighi A, Albert MA; on behalf of the American Heart Association Cardiovascular Disease and Stroke in Women and Special Populations Committee of the Council on Clinical Cardiology, Council on Cardiovascular Nursing, Council on High Blood Pressure Research, and Council on Nutrition, Physical Activity and Metabolism. Fifteen-year trends in awareness of heart disease in women: results of a 2012 American Heart Association national survey. Circulation 2013;127:1254–1263, e1–e29. doi: 10.1161/CIR.0b013e318287cf2f. - DOI - PMC - PubMed
    1. Weaver LC, Jessup A, Mayer DK. Cancer survivorship care: implications for primary care advanced practice nurses. Nurse Pract 2013;38:1–11. doi: 10.1097/01.NPR.0000435784.40143.62. - DOI - PubMed
    1. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, Correa C, Cutter D, Gagliardi G, Gigante B, Jensen MB, Nisbet A, Peto R, Rahimi K, Taylor C, Hall P. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013;368:987–998. doi: 10.1056/NEJMoa1209825. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources